Prevention and Treatment of HIV-1 - Eisenhower

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/53

encourage image

There's no tags or description

Looks like no tags are added yet.

54 Terms

1
New cards

Goals of HIV Prevention

  1. Prescribe safe and effective medication to patients who are HIV negative to reduce risk of acquisition

  2. Provide appropriate medication education and support for medication adherence to patients.

  3. Provie HIV risk reduction support and prevention services

  4. Provide effective contraception to persons with childbearing potential who are taking PrEP and do not wish to become pregnant

  5. Monitor for HIV infection, medication-related adverse events and level of risk behaviors

  6. Reduce risk for HIV-1 infection after non-occupational exposure to blood, genital secretion, and other bodily fluids that may contain HIV


2
New cards

Pre-Exposure Prophylaxis (PrEP)

Fixed dose combination treatments are safe and effective for reducing HIV acquisition in MSM, gay men, and women in HIV sero-different couples.


3
New cards

What patient populations are recommended to receive PrEP

Sexually active adults or adolescents (>/=35kg) having anal or vaginal sex in past 6 months AND have any of the following:

  • Sexual Partner who is positive for HIV

  • Certain bacterial STI in past 6 months

  • History of inconsistent or no condom use with sexual partner

Persons who inject drugs:

  • With injecting partner who is positive for HIV

    • Sharing injection Equipment


4
New cards

PrEP regimen

Emtricitabine plus Tenofovir (TAF/TDF)

5
New cards

Who should use Emtricitabine + Tenofovir (Truvada)

Cisgender men or cisgender women: includes persons at risk due to sexual behaviors or injection drug use

Cisgender men or transgender women: includes persons at risk due to sexual behaviors but not studied for cisgender women at risk from receptive vaginal sex. Transgender women risk is due to sex with men.

6
New cards

Dosing for Truvada PrEP (cisgender women + cisgender men)

Emtricitabine 200mg + 300mg TDF PO QD

7
New cards

Dosing for Descovy PrEP (cisgender men or transgender women)

Emtricitabine 200mg + TAF 25mg PO QD

8
New cards

Long Acting Injectable Cabotegravir (CAB-LA)

PrEP option. INSTI

FDA Approved for adults >19 and adolescents 10-19 at risk for HIV-1 (>35kg) who are HIV negative prior to initiation. May be offered as additional prevention for people at substantial ongoing risk of HIV-1

May start with oral CAB (Vocabria) QD for 4 weeks to evaluate tolerability and then start injection on the last day or oral dose or within 3 days of last oral dose.

9
New cards

CAB-LA Dosing and administration (Initiation)

600mg IM x 2 given 4 weeks apart

10
New cards

CAB-LA Dosing and administration (Maintenance)

600mg IM q 8 weeks

11
New cards

CAB-LA missed dose

Planned: if scheduled injection will be missed by >7 days, take oral CAB for up to 2 months. Restart injection on last day of daily oral dose or within 3 days.

12
New cards

LEN-LA

PrEP. Long-acting injectable Lenacapavir. Capsid inhibitor.

FDA approved for adolescents weighing at least 35kg who are at risk of HIV-1 acquisition. Highly effective, may increase adherence

13
New cards

LEN-LA dosing and administration

Day 1: 927mg SC injection plus 600mg by mouth (2×300mg tabs)

Day 2L 600mg by mouth (2×300mg tabs)

Continuation 927mg injection q6 months from the date of last injection, ± 2 weeks

14
New cards

LEN-LA missed dose

Planned: if scheduled injection will be missed by more than 2 weeks, may use oral tablets (300mg PO q7 days) on an interim bases for up to 6 months if needed until injections resume.

Unplanned: if more than 28 weeks have elapsed since the last injection and tablets have not been taken, restart initiating from Day 1 if clinically appropriate

15
New cards

PrEP monitoring

Renal function with use of emtricitabine plus Tenofovir: assess CrCl at baseline and at least annually

HIV Ag/Ab testing:

  • If daily oral PrEP: q3 months

  • if CAB-LA: q4 months

  • if LEN-LA: before each injection as appropriate

Always provide adherence support for medication adherence and access, and education appropriate non-pharmacologic preventative methods


16
New cards

Can patient who just started taking PrEP engage in sexual activity with an HIV positive person

CDC: Takes 7 days of daily use to maximize protection from anal sex, and 21 days for vaginal sex

NHS: Wait 7 days before either sex. If patient wishes to engage before day 7, take 2 tabs 2 hours prior and then 1 tablet QD.

WHO: Says PrEP reaches protection after 7 doses. 4 doses for anal and 7 doses for vaginal

17
New cards

PEP

Post Exposure Prophylaxis

18
New cards

Non-occupational PEP (nPEP)

Applies to patients with sexual, injection drug use, or other non-occupational exposure to HIV.

19
New cards

When is nPEP recommended

When exposure occurred within past 72 hours that presents substantial risk for HIV transmission and the source has HIV without sustained viral suppression or viral suppression in not known.

Case-by-case determination is required when exposure has occurred within past 72 hours that presents substantial risk for HIV transmission but not known whether source has HIV.

20
New cards

Laboratory Assessment and monitoring for nPEP - initial visit

Rapid, lab based Ag/Ab HIV test

If patient has LA PrEP exposure in past 6 months, add diagnostic HIV nucleic acid test

Routine labs: SCr, ALT/AST, HBV, pregnancy testing

Based on clinical situation: HCV, STIs

21
New cards

Laboratory Assessment and monitoring for nPEP - 4-6 weeks post exposure

lab-based Ag/Gb HIV test and diagnostic HIV NAT

4-6

22
New cards

Laboratory Assessment and monitoring for nPEP - 12 weeks post exposure

lab-based Ag/Ab HIV test and diagnostic HIV NAT

23
New cards

Treatment duration for nPEP adults

28 days

24
New cards

Administration of nPEP for adults

With or without food

25
New cards

Spacing of nPEP for ADults

2 hours before or 6 hours after medications with polyvalent cations such as aluminum, calcium, iron, or magnesium. Alternatively calcium and iron can be taken with either nPEP regimen with food

26
New cards

nPEP regimens

  1. Bictegravir 50mg + Emtricitabine 200mg/TAF 25mg PO QD

  2. Dolutegravir 50mg + TAF 25mg or TDF 300mg + Emtricitabine 200mg or lamivudine 300 mg PO QD


27
New cards

nPEP regimen selection

Individualized based on comorbidities, pregnancy, potential for DDIs, previous exposure to ART regimens, history of course of HIV exposure, and factors that may influence adherence

28
New cards

Factors that may impact adherence

Pill burden

Dosing Frequency

Formulation

Side effects

cost

Access

29
New cards

nPEP to PrEP

Immediate transition to PrEP at the completion of nPEP may be beneficial for persons with anticipated repeat or ongoing potential exposures to HIV.

30
New cards

Occupational PEP for Healthcare Personnel

Workplaces have standard precautions including appropriate personal protective equipment to prevent HIV exposure from blood, tissue, specific bodily fluids, contaminated medical supplies and equipment, and/or contaminated environmental surfaces.

Need to determine whether source of exposure is positive for HIV and initiate PEP as soon as possible.

31
New cards

Initiation of oPEP

Initiate oPEP as soon as possible, up to 72 hours following exposure. After 72 hours consider initiation after consulting with expert, if exposure is though to present high risk of transmission. Determine HIV status of source whoever possible but do not delay initiation of oPEP while waiting.

32
New cards

Preferred oPEP regimens

  1. Bictegravir 50mg + Emtricitabine 200mg/TAF 25mg PO QD

  2. Dolutegravir 50mg + TAF 25mg or TDF 300mg + Emtricitabine 200mg or lamivudine 300 mg PO QD


33
New cards

Treatment duration of oPEP

28 days

34
New cards

Administration of oPEP

With or without food

35
New cards

Spacing of oPEP

2 hours before or 6 hours after medications with polyvalent cations such as aluminum, calcium, iron, and/or magnesium iron. Alternatively, calcium and iron can be taken with either nPEP regimen with food.

36
New cards

Goals of HIV-1 Treatment

Reduce HIV associated morbidity and prolong duration and quality of survival

Restore and preserve immunologic function

Undetectable viral load/viral suppression (HIV RNA)

Reduce risk of sexual transmission of HIV-1

Reduce risk of perinatal transmission of HIV-1

37
New cards

What is considered to be undetectable or untransmittable viral load

<200 copies/mL

38
New cards

What is considered to be virologically suppressed

<50 copies/mL

39
New cards

When is the initiation of ART recommended

For all persons with HIV, regardless of CD4 count, to reduce morbidity and mortality associated with HIV infection and to prevent transmission to others. Initiate ASAP after diagnosis to increase uptake of ART and improve viral suppression.

40
New cards

How to prevent Sexual transmission at Initiation of ART

Maintain HIV RNA <200 copies to prevent sexual transmission

At initiation of ART use another form of protection for at least 6 months until suppression of viral load is confirmed. Remind patients that an HIV viral load <200 does not prevent other STI transmission/acquisition

41
New cards

PLWH who rely on ART

Must maintain high levels of adherence and should be aware that transmission is possible during period of poor adherence or treatment interruption

42
New cards

ART regimen options for patients without history of CAB-LA use for PrEP

Bictegravir/TAF/Emtricitabine

Dolutegravir/Tenofovir/Emtricitabine or lamivudine

Dolutegravir/lamivudine

43
New cards

Dolutegravir/lamivudine ART counter indications

Patients with HBV co-infection

Unknown HBV serostatus

Without results from genotypic resistance testing for reverse transcriptase

Planning rapid initiation of ART

44
New cards

ART regimen for patients with history of CAB-LA for PrEP

Should first perform INSTI genotypic resistance testing

Darunavir/Cobicistat/Tenofovir/Emtricitabine or Lamivudine

45
New cards

Reasons to optimize ART is patients with viral suppression

Simplify a regimen by reducing pill burden or dosing frequency

Enhance tolerability and decrease toxicities

Prevent or mitigate drug-drug interaction

Eliminate food requirement with administration of ART

Switch to long-acting injectable regimen for convenience

Allow optimal use during pregnancy

Reduce costs of therapy

46
New cards

Bictegravir/Lenacapavir (Bixlenvo)

Approved for patients with HIV-1 who are virologically suppressed based on HIV RNA less than 50 copies on a stable regimen with no concerns for resistance to either agent in the 2-drug combination .

47
New cards

Bictegravir/Lenacapavir (Bixlenvo) renal impairment

no dosage adjustment needed if CrCl >15mL/min no data for <15

48
New cards

Bictegravir/Lenacapavir (Bixlenvo) hepatic impairment

no dosage adjustment needed for child-pugh A or B

No data for C

49
New cards

Assessment for virologic failure

ART adherence, interactions with other drugs or food, drug tolerability, trends in HIV RNA and CD4 count, ART history, current drug resistance test results.

50
New cards

Drug resistance test

Perform while patient is taking failing regimen or within 4 weeks of DC non-long acting forms of ART regimen to best evaluate resistance mutations

51
New cards

If virologic failure occurs what should the new regimen consist

Two fully active drugs if at least one has high resistance barrier (like a second generation INSTI or boosted protease inhibitor)

52
New cards

What should a patient do if they are experiencing Virologic failure

They should not DC or interrupt ART. DC or brief interruption may lead to rapid increase in viral load, decrease in CD4 count, and/or clinical progression of HIV-1

53
New cards

Promoting adherence

Patients must be committed to lifelong adherence

Assess patients for clinical and/or psychological factors that may interfere with timely initiation of ARV and/or adherence

Assess barriers such as medication access, cost, and health literacy

Evaluate eligibility for single-pill complete regimens

54
New cards

Cost and Coverage Considerations

Consider out of pocket costs for PLWH when selecting regimens.

Insurance and prescription drug coverage can directly impact clinical outcomes for PLWH and lapses in coverage may result in lapses in viral suppression.

Collaborate with healthcare team and patient/caregivers to modify ART regimens if costs/coverage present barriers to initiation, adherence, or continuation of ART.

Modification of ART should not compromise virologic efficacy or long-term treatment outcomes